3rd Jul 2007 07:01
International Medical Devices PLC03 July 2007 3 July 2007 International Medical Devices Plc ("IMD" or "the Company") Updates on Performance of Trading Divisions and Subsidiaries EMS Medical Ltd launches INOGEN One and Operational Update on Safety Needles and own brand of Medical Consumables and CPAP - Successful Launch of INOGEN One, the smallest and lightest oxygen concentrator worldwide - Significant progress with "Clip-On" safety needles resulting in full launch in September - Response consumables successfully launched for cardiac monitoring - Sale of CPAP into ambulance services in the South West with huge market potential Inogen One EMS Medical Ltd ("EMS), the aged care operating division of InternationalMedical Devices PLC (AIM: INT) is pleased to announce the successful launch ofits newest product the INOGEN One oxygen concentrator. Inogen One is thesmallest and lightest oxygen concentrator available today worldwide, offeringpatients a level of mobility and freedom not provided by any other system. Following the success of Inogen One in the US, EMS Medical has already sold over35 systems worth over £120,000 (at retail prices) and successfully appointedfour distributors in the UK. Distributors have also been appointed in Kuwait,Saudi Arabia, Dubai, Norway, Sweden and Finland. Several national distributors have been appointed in the UK market to handledirect consumer enquiries from both the private and NHS markets. Trials havecommenced with national oxygen suppliers contracted by the NHS to supply oxygento COPD sufferers in the UK. Inogen One has been launched in the UK with the first ever direct consumeradvertising campaign aimed at the oxygen therapy market through a press campaignin national newspapers. This has produced a high level of consumer enquiries.Over US $100,000 is being invested in the campaign in the July to Septemberperiod. EMS Medical commences the first National TV advertising campaign today,involving 500 TV slots of Inogen One portrayed as an innovative lifestyleadvertisement showing the patient benefits of the system in promoting a moreactive lifestyle. A national magazine advertising campaign is scheduled for theend of July. Based on positive initial sales, EMS Medical estimates it will secure a majormarket share of the independent oxygen supply market in the UK for the InogenOne system within the next six months. Further growth prospects are expectedfrom within the NHS. There are an estimated 80,000 sufferers of COPD in the UKwho are oxygen dependent (according to the British Heart and Lung Foundation).The US market experience has seen a shift in recent years away from bottledoxygen cylinders towards the use of devices like Inogen One. EMS Medical hasapplied for FP10 status (available on prescription) for Inogen One. Chris Thomas, Chief Executive of International Medical Devices said; "Inogen Oneshould be a major driver in sales growth for the Company, along with the otherprojects for 2008. This is a very encouraging time and we look forward to ourgrowth in the UK and export markets." Safety Needles Following the Interim Report and Chief Executive Officer's Webcast announcementof 27th March, significant progress has been made with the manually retractablehypodermic safety needle, "Clip-On". In response to feedback from clinicians in the NHS, in private medicine andoverseas, a number of design iterations have been made to the safety needle bythe Company's design and engineering team. Following a lengthy due diligence process, the Company has now appointed apreferred OEM needle manufacturer who has already begun production of the safetyneedle. It has agreed to deliver the first batch of 20,000 needles,incorporating the design modifications, before the end of July. These deviceswill be used for more in-depth product evaluations in various sectors of thehealthcare industry and the veterinary market. A second batch of 5,000,000needles will be ordered for launch in September. IMD also announces that it will be following up the launch of its manuallyretractable hypodermic safety needle with the introduction of a range of safeblood collection and IV injection devices. This expanded range recently had atrade mark application accepted. The Company expects to reveal more detailsabout the branding of the range nearer the launch date of the needle inSeptember. IMD plans to launch the whole range of safety needle, bloodcollection and IV injection products by the end of 2008 to coincide with theanticipated legislative amendment to EU law mandating the use of safety devices. The Company is working with the government organisation, UK Trade & Investment,to identify and appoint distributors for products in its safety needles range inthe main target markets in which it owns patents; US, Canada, Spain, France,Sweden, Italy and Netherlands. Response Medical Equipment Ltd - Medical Consumables IMD is proud to announce the launch of a range of branded consumables at its100% owned subsidiary, Response Medical Equipment Ltd. The launch of a range of consumables products for cardiac monitoring devices iscurrently under way, with Response Medical's Q-Cuff range already being taken upat three NHS hospital trusts in the first few weeks. The Company has also launched a range of own-brand ECG chart paper comprising 39lines of product. Of these, 16 lines have now been sold to NHS trusts. Response Medical-branded Cables and Leadwires and SpO2 sensors are to be rolledout to the direct sales team at Response Medical over the next two months. John Butler, Chairman of Response Medical and Director of IMD, said: "The growtharea for the Company in the short term is definitely Consumables. Sourcingmanufacture for our own-branded products not only strengthens our name in themarket but also offers much higher margins." CPAP (Continuous Positive Airway Pressure) CPAP is a very effective treatment for patients suffering from Congestive HeartFailure (CHF) or Chronic Obstructive Pulmonary Disease (COPD), conditionsaffecting over 800,000 patients in UK each year. It is used extensively inhospitals and for the treatment of sleep apnoea, but unlike other countries inEurope, UK has been slow to adopt the technique in the Ambulance Sector. Response Medical announces the first sales of CPAP devices to an AmbulanceService in UK at South Western Ambulance Service NHS Trust. The trust comprisesDorset, Somerset, Devon and Cornwall, where the first 47 CPAP units are beingdeployed on emergency ambulances and fast response vehicles. Richard Taffler, Clinical Effectiveness Officer for the Trust commented: "SouthWestern Ambulance Service is proud to be the first Ambulance Service in UK toadopt the Whisperflow CPAP system in the pre-hospital setting. We are committedto providing the very highest level of care for our patients. I believe thiscould now lead to the introduction of CPAP on every one of UK's 5000 front lineambulances." In addition to the opportunities for hardware sales, the pre-hospital market forCPAP masks and consumables is believed to be in the region of £13m per year andthe Company regards its success at South Western Ambulance Service as the 'tipof the iceberg'. Response Medical has an exclusive UK distribution agreement for the pre-hospitalmarket with US CPAP manufacturer, Respironics Inc (NASDAQ Global Select Market:RESP). Managing Director of Respironics UK, Kal Vaikla paid tribute to the work ofResponse Medical: "The UK pre-hospital market has been an extremely difficultsector to penetrate. I am delighted with the work of the team at ResponseMedical and particularly pleased that the Respironics WhisperFlow(R) system isthe first to be adopted by the Emergency Services here in UK." The Company now expects other UK Ambulance Services to follow the lead of SouthWestern. Ends For further information, contact: International Medical Devices JM Finn Parkgreen CommunicationsChris Thomas Geoff Nash Clare IrvineCEO +44 207 6289688 +44 207 851 7480+44 203 008 4960 Notes to Editors: International Medical Devices Plc is one of the UK's leading medical devicesupplier groups. It also owns significant distribution and technology rightsthroughout North America and most of Europe. The group was floated on AIM inNovember 2004 with the purpose of acquiring companies or businesses operating inthe health and medical devices sectors which have the prospect of deliveringhigh returns and significant capital growth. For further information on the Company and its subsidiaries, please visitwww.imd-plc.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Intelliam Ai